These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 33207584)
1. The Case for Intermittent Carbapenem Dosing in Stable Haemodialysis Patients. Ho V; Tay F; Wu JE; Lum L; Tambyah P Antibiotics (Basel); 2020 Nov; 9(11):. PubMed ID: 33207584 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
3. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
4. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL; JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454 [TBL] [Abstract][Full Text] [Related]
5. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846 [TBL] [Abstract][Full Text] [Related]
6. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL Trials; 2015 Jan; 16():24. PubMed ID: 25623485 [TBL] [Abstract][Full Text] [Related]
7. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028 [TBL] [Abstract][Full Text] [Related]
8. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Mohr JF Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049 [TBL] [Abstract][Full Text] [Related]
9. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems]. Kuzucu C; Yetkin F; Görgeç S; Ersoy Y Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156 [TBL] [Abstract][Full Text] [Related]
10. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Hsueh PR; Chen WH; Luh KT Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243 [TBL] [Abstract][Full Text] [Related]
11. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections. Ny P; Nieberg P; Wong-Beringer A Am J Infect Control; 2015 Oct; 43(10):1076-80. PubMed ID: 26190386 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital. Patel GW; Duquaine SM; McKinnon PS Pharmacotherapy; 2007 Dec; 27(12):1637-43. PubMed ID: 18041884 [TBL] [Abstract][Full Text] [Related]
13. Patterns of Drug-Resistant Bacteria in a General Hospital, China, 2011-2016. Mao T; Zhai H; Duan G; Yang H Pol J Microbiol; 2019; 68(2):225-232. PubMed ID: 31250593 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study. Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312 [TBL] [Abstract][Full Text] [Related]
16. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics. Chen M; Buurma V; Shah M; Fahim G Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562 [TBL] [Abstract][Full Text] [Related]
18. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Perrott J; Mabasa VH; Ensom MH Ann Pharmacother; 2010 Mar; 44(3):557-64. PubMed ID: 20124468 [TBL] [Abstract][Full Text] [Related]
19. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase. Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301 [TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977 [No Abstract] [Full Text] [Related] [Next] [New Search]